Lactobacillus acidophilus LA85: Targeted Relief for Troubled Colons

Ulcerative colitis (UC) is a lifelong condition marked by painful flares, limited drug options, and a gut microbiota in disarray. This 21-day trial set out to test whether a daily dose of Lactobacillus acidophilus LA85 could deliver measurable relief in the DSS treated mouse model with UC.

Its significance lies in three clear outcomes:
 1. Calmer Digestion – LA85-fed mice lost less weight, posted lower Disease Activity Index scores, and retained near-normal colon length. Histology revealed smoother tissue and fewer lesions, translating to less bleeding and looser stools.
 2. Balanced Immunity – Serum pro-inflammatory cytokines TNF-α and IL-6 dropped, whereas the anti-inflammatory signal IL-10 rebounded. helping the gut fight inflammation without overreacting.

3. Microbiome restoration with lasting effect – LA85 rebuilt diversity, boosted helpful Akkermansia and Romboutsia, and pushed back pathogens such as Escherichia/Shigella. Remarkably, these gains persisted for weeks after intervention, suggesting a durable ecosystem support .
These findings position LA85 as a science-backed probiotic candidate that tackles UC, symptom relief, immune equilibrium, and microbiota repair. Formulate with LA85 to offer a sciencebacked solution that helps customers feel relief, offering a compelling alternative or complement to conventional therapies.